
    
      The purpose of this study is to determine whether radotinib 400mg bid is effective and safe
      for patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to
      prior 2 or more tyrosine kinase inhibitors. The primary end point is major cytogenetic
      response by 12 months.
    
  